Expedited Access to Biosimilars Act

Bill Number

S. 1414

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-04-10: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Last Updated

2025-07-01T11:06:18Z

AI-Generated Summary

Purpose of the Legislation

The "Expedited Access to Biosimilars Act" (S. 1414) aims to streamline the approval process for biosimilar biological products—medicines similar to existing biologic drugs, like insulin or vaccines, but produced by different manufacturers. By reducing mandatory requirements for certain scientific assessments in clinical studies, the bill seeks to speed up market access to these lower-cost alternatives, potentially making treatments more affordable.

Key Provisions

• Amendments to the Public Health Service Act: The bill modifies Section 351(k)(2)(A) of the Act, which governs the licensure of biosimilars by the Food and Drug Administration (FDA).
• Requires clinical studies to assess pharmacokinetics (how the drug moves through the body) to demonstrate safety, purity, and potency.
• Mandates clinical studies sufficient to show safety, purity, and potency for specific medical uses where the original (reference) product is licensed.
• Discretionary Assessments: The FDA Secretary may require additional evaluations in clinical studies, such as:
• Immunogenicity (the drug's potential to trigger an immune response).
• Pharmacodynamics (the drug's effects on the body).
• Comparative clinical efficacy (how well the biosimilar performs compared to the original drug).
• These can only be mandated if the FDA provides early written notice and justification to the applicant before the application filing deadline.
• Applicability: Changes apply to biosimilar applications submitted on or after the date the bill is enacted.

Significant Changes to Existing Law

• Under current law, biosimilar approvals often require extensive studies, including routine assessments of immunogenicity, pharmacodynamics, and comparative efficacy to prove similarity to the reference product.
• The bill shifts these from mandatory to discretionary, giving the FDA flexibility to waive them unless justified on a case-by-case basis. This replaces broader, automatic requirements with targeted ones focused on essential safety and effectiveness data.

Potential Impacts

• On Government Agencies: The FDA may see reduced administrative burden from fewer mandatory studies, allowing faster reviews, but it could require more upfront justifications for additional requirements.
• On Citizens: Patients could gain quicker access to affordable biosimilars, lowering healthcare costs for chronic conditions treated by biologics (e.g., cancer or autoimmune diseases).
• On International Relations: Minimal direct impact, though faster U.S. approvals might influence global biosimilar markets by encouraging competition with foreign manufacturers.
• Overall, the bill could boost biosimilar adoption, potentially saving billions in healthcare spending, but it risks overlooking rare side effects if assessments are skipped.

Main Stakeholders Affected

• Biosimilar Manufacturers: Benefit from a less burdensome approval path, enabling faster and cheaper entry into the market.
• Innovator Drug Companies (makers of reference biologics): May face increased competition, potentially reducing their market exclusivity and profits.
• Patients and Healthcare Providers: Gain from more options and lower prices for biologic treatments.
• FDA and Regulators: Must balance efficiency with safety oversight, adapting processes for case-specific decisions.
• Payers (e.g., Insurance Companies): Could reduce costs through greater biosimilar availability.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens the existing biosimilar pathway under the 2010 Biologics Price Competition and Innovation Act by clarifying FDA discretion, potentially reducing litigation over approval requirements. No challenges to enforceability are evident.
• Constitutional: Aligns with Congress's authority to regulate public health and interstate commerce; no apparent free speech, due process, or other rights issues.
• Political: Promotes deregulation in pharmaceuticals to enhance affordability, appealing to advocates of market competition, but critics may argue it compromises drug safety standards. As a Senate-introduced bill (by Sen. Rand Paul), it reflects efforts to address high drug prices amid ongoing debates on healthcare reform.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Paul, Rand [R-KY]

Cosponsors (1)

Sen. Lee, Mike [R-UT]

Recent Actions

• 2025-04-10: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
• 2025-04-10: Introduced in Senate

Bill Versions

• Expedited Access to Biosimilars Act — issued 2025-04-10 — PDF (4 pages)